WMT

125.06

+0.47%↑

COST

996.69

-0.91%↓

155.8

+0.19%↑

77.76

-0.15%↓

172.1

-0.55%↓

WMT

125.06

+0.47%↑

COST

996.69

-0.91%↓

155.8

+0.19%↑

77.76

-0.15%↓

172.1

-0.55%↓

WMT

125.06

+0.47%↑

COST

996.69

-0.91%↓

155.8

+0.19%↑

77.76

-0.15%↓

172.1

-0.55%↓

WMT

125.06

+0.47%↑

COST

996.69

-0.91%↓

155.8

+0.19%↑

77.76

-0.15%↓

172.1

-0.55%↓

WMT

125.06

+0.47%↑

COST

996.69

-0.91%↓

155.8

+0.19%↑

77.76

-0.15%↓

172.1

-0.55%↓

Strona główna・Stock List・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Closed

SectorConsumer defensive

6.87 -1.86

Buy Sell

Overview

Share price change

24h

Current

Min

6.3

Max

7.16

Key metrics
By Trading Economics
Income	-7.9M -10M
Sales	-5.3M 31M
Profit margin	-32.116
Employees	406

Dividends
By Dow Jones
Next Earnings	16 mar 2026

Market Stats
By TradingEconomics
Market Cap	-9.8M 231M
Previous open	8.73
Previous close	6.87

News Sentiment

By Acuity

25%

75%

15 / 131 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 mar 2026, 20:38 UTC

Earnings

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mar 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10 mar 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mar 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mar 2026, 23:35 UTC

Market Talk

Major News Events

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mar 2026, 23:06 UTC

Earnings

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mar 2026, 22:51 UTC

Major News Events

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mar 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mar 2026, 21:21 UTC

Earnings

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mar 2026, 21:15 UTC

Earnings

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mar 2026, 21:15 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mar 2026, 21:14 UTC

Earnings

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mar 2026, 21:13 UTC

Earnings

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mar 2026, 21:12 UTC

Earnings

Franco-Nevada 4Q Rev $597.3M >FNV

10 mar 2026, 21:12 UTC

Earnings

Franco-Nevada 4Q EPS $1.90

10 mar 2026, 20:57 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

10 mar 2026, 20:44 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:34 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

10 mar 2026, 20:34 UTC

Market Talk

Earnings

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mar 2026, 20:23 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:16 UTC

Earnings

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mar 2026, 20:14 UTC

Earnings

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mar 2026, 20:14 UTC

Earnings

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mar 2026, 20:13 UTC

Earnings

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mar 2026, 20:12 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Peer Comparison

Price change

Lifecore Biomedical Inc Forecast

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Lifecore Biomedical Inc - Dist in the past 3 months.

Sentiment

By Acuity

15 / 131 Ranking in Consumer defensive

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.